Crizotinib (PF-02341066)

For research use only. Not for use in humans.

Pfizer辉瑞授权目录号：S1068

Crizotinib (PF-02341066) Chemical Structure

Molecular Weight(MW): 450.34

Crizotinib (PF-02341066) 克唑替尼是一种有效的c-Met和ALK抑制剂，在细胞试验中IC50分别为11 nM 和 24 nM。它同时也是有效的ROS1抑制剂，其Ki值小于0.025 nM。Crizotinib可在多种肺癌细胞系中通过抑制STAT3通路来诱导自噬。

规格

价格

库存

购买数量

10mM (1mL in DMSO)	RMB 1812.55	现货
5mg	RMB 900.49	现货
10mg	RMB 1372.81	现货
50mg	RMB 4681.47	现货
大包装	有超大折扣

大剂量询单有大折扣！

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的Crizotinib (PF-02341066)发表文献255篇：

Cancer Cell, 2020, 13;37(1):104-122e12

PubMed: 31935369 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Nat Med, 2018, 24(7):968-977

PubMed: 29808010 ( click the link to review the publication )

Cell, 2018, 174(4):856-869

PubMed: 30096312 ( click the link to review the publication )

Cancer Cell, 2018, 34(6):922-938

PubMed: 30537514 ( click the link to review the publication )

Nat Chem Biol, 2017, 13(6):681-690

PubMed: 28437395 ( click the link to review the publication )

Nature, 2016, 30;534(7609):647-51.

PubMed: 27338794 ( click the link to review the publication )

J Clin Oncol, 2016, 34(8):794-802

PubMed: 26215952 ( click the link to review the publication )

Nat Med, 2015, 21(9):1038-47

PubMed: 26301689 ( click the link to review the publication )

Cancer Discov, 2015, 5(9):960-971

PubMed: 26036643 ( click the link to review the publication )

Cancer Discov, 2015, 10.1158/2159-8290.CD-15-0913

PubMed: 26566875 ( click the link to review the publication )

Cancer Cell, 2015, 27(3):397-408

PubMed: 25759024 ( click the link to review the publication )

Cancer Cell, 2015, 27(4):533-46

PubMed: 25873175 ( click the link to review the publication )

Cancer Discov, 2014, 4(12):1398-405

PubMed: 25266736 ( click the link to review the publication )

Cancer Cell, 2014, 26(2):207-21

PubMed: 25065853 ( click the link to review the publication )

Nat Med, 2013, 19(11):1469-1472

PubMed: 24162815 ( click the link to review the publication )

Nature, 2012, 26;487(7408):505-9.

PubMed: 22763448 ( click the link to review the publication )

Cell, 2012, 21;151(5):937-50.

PubMed: 23178117 ( click the link to review the publication )

Nat Med, 2012, 18(6):883-91

PubMed: 22635005 ( click the link to review the publication )

Nat Med, 2011, 17(9):1116-20

PubMed: 21822287 ( click the link to review the publication )

Cancer Cell, 2011, 19(5):679-90

PubMed: 21575866 ( click the link to review the publication )

Nat Commun, 2020, 25;11(1):1556

PubMed: 32214092 ( click the link to review the publication )

Sci Adv, 2020, 22;6(21):eaaz8521

PubMed: 32494745 ( click the link to review the publication )
Dev Cell, 2020, 4;53(3):344-357 e5

PubMed: 32302545 ( click the link to review the publication )

Clin Cancer Res, 2020, 10.1158/1078-0432.CCR-19-3608

PubMed: 32034073 ( click the link to review the publication )

Clin Cancer Res, 2020, 8

PubMed: 32269053 ( click the link to review the publication )

Clin Cancer Res, 2020, 10.1158/1078-0432

PubMed: 32034078 ( click the link to review the publication )

Genome Med, 2020, 18;12(1):17

PubMed: 32070411 ( click the link to review the publication )

Cancers (Basel), 2020, 27;12(5)pii: E1087

PubMed: 32349331 ( click the link to review the publication )

Cancers (Basel), 2020, 13;12(2) pii: E436

PubMed: 32069833 ( click the link to review the publication )

Cancer Discov, 2020, 1 pii: CD-19-1030

PubMed: 32238360 ( click the link to review the publication )

Am J Cancer Res, 2020, 10(2):403-423

PubMed: 32195017 ( click the link to review the publication )

Lung Cancer, 2020, 144:20-29

PubMed: 32353632 ( click the link to review the publication )

J Cell Physiol, 2020, 10.1002/jcp.29463

PubMed: 31960422 ( click the link to review the publication )

J Cell Sci, 2020, 11;133(9) pii: jcs241505

PubMed: 32184261 ( click the link to review the publication )

Antiviral Res, 2020, 178:104790

PubMed: 32272175 ( click the link to review the publication )

Int J Mol Sci, 2020, 18;21(8):2825

PubMed: 32325639 ( click the link to review the publication )

Sci Rep, 2020, 10(1):218

PubMed: 31937834 ( click the link to review the publication )

Cancer Cell Int, 2020, 19;20:58

PubMed: 32099531 ( click the link to review the publication )

Oncol Rep, 2020, 43(3):817-826

PubMed: 32020234 ( click the link to review the publication )

Anticancer Res, 2020, 40(1):109-119

PubMed: 31892559 ( click the link to review the publication )

Anticancer Res, 2020, 40(3):1395-1403

PubMed: 32132036 ( click the link to review the publication )

Blood Adv, 2020, 4(5):819-829

PubMed: 32126142 ( click the link to review the publication )

Mol Cancer Res, 2020, 18(4):549-559

PubMed: 31941753 ( click the link to review the publication )

J Thorac Oncol, 2020, 15(5):752-765

PubMed: 31972351 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2532

PubMed: 31182717 ( click the link to review the publication )

Nat Commun, 2019, 10(1):3991

PubMed: 31488816 ( click the link to review the publication )
Nat Commun, 2019, 10(1):4343

PubMed: 31554817 ( click the link to review the publication )

Clin Cancer Res, 2019, clincanres.1486.2019

PubMed: 31636099 ( click the link to review the publication )

EMBO Mol Med, 2019, 10.15252/emmm.201910581

PubMed: 31633304 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-19-1667

PubMed: 31548343 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432

PubMed: 31776128 ( click the link to review the publication )

Cancer Res, 2019, 79(3):546-556

PubMed: 30538120 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-19-1104

PubMed: 31585938 ( click the link to review the publication )

Cell Rep, 2019, 28(9):2331-2344

PubMed: 31461650 ( click the link to review the publication )

Cell Rep, 2019, 26(1):65-78

PubMed: 30605687 ( click the link to review the publication )

Oncogene, 2019, 101038/s41388-019-1136-4

PubMed: 31804622 ( click the link to review the publication )

Oncogene, 2019, 38(11):1936-1950

PubMed: 30390071 ( click the link to review the publication )

EBioMedicine, 2019, 42:326-339

PubMed: 30879923 ( click the link to review the publication )

Cancers (Basel), 2019, 11(9)

PubMed: 31547367 ( click the link to review the publication )

Cell Death Dis, 2019, 10(9):663

PubMed: 31506424 ( click the link to review the publication )

Cell Death Dis, 2019, 10(2):139

PubMed: 30760701 ( click the link to review the publication )

Cells, 2019, 8(12)

PubMed: 31795298 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(3):718-725

PubMed: 30755456 ( click the link to review the publication )

Front Oncol, 2019, 9:579

PubMed: 31334113 ( click the link to review the publication )

Front Oncol, 2019, 9:579

PubMed: 31380285 ( click the link to review the publication )

Cancer Sci, 2019, 110(11):3584-3594

PubMed: 31446643 ( click the link to review the publication )

Biochem Pharmacol, 2019, 166:128-138

PubMed: 31078602 ( click the link to review the publication )

Toxicol Sci, 2019, 10.1093/toxsci/kfz123

PubMed: 31132080 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(17)

PubMed: 31480591 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2019, 383:114768

PubMed: 31639374 ( click the link to review the publication )
Invest New Drugs, 2019, 10.1007/s10637-019-00795-3

PubMed: 31124056 ( click the link to review the publication )

BMC Cancer, 2019, 19(1):1044

PubMed: 31690270 ( click the link to review the publication )

Cancer Res Treat, 2019, 51(3):1231-1240

PubMed: 30653748 ( click the link to review the publication )

Cancer Res Treat, 2019, 51(3):951-962

PubMed: 30309221 ( click the link to review the publication )

Molecules, 2019, 24(3)

PubMed: 30754629 ( click the link to review the publication )

Transl Oncol, 2019, 12(1):116-121

PubMed: 30290287 ( click the link to review the publication )

Biochem Biophys Res Commun, 2019, 511(2):260-265

PubMed: 30791979 ( click the link to review the publication )

Future Oncol, 2019, 15(22):2585-2593

PubMed: 31339066 ( click the link to review the publication )

Leuk Res, 2019, 78:12-20

PubMed: 30660961 ( click the link to review the publication )

J Thorac Oncol, 2019, 14(10):1753-1765

PubMed: 31279006 ( click the link to review the publication )

Nat Biomed Eng, 2018, 2(8):578-588

PubMed: 31015631 ( click the link to review the publication )

Nat Chem Biol, 2018, 14(8):768-777

PubMed: 29942081 ( click the link to review the publication )

J Clin Invest, 2018, 128(1):446-462

PubMed: 29202477 ( click the link to review the publication )

J Clin Invest, 2018, 128(9):4086-4097

PubMed: 29990309 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(13):3126-3136

PubMed: 29618618 ( click the link to review the publication )

Leukemia, 2018, 32(9):1994-2007

PubMed: 29588546 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2018, 115(26):E6030-E6038

PubMed: 29875142 ( click the link to review the publication )

Cell Syst, 2018, 6(3):329-342

PubMed: 29550255 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(12):2732-2739

PubMed: 29559559 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(23):6066-6077

PubMed: 30061362 ( click the link to review the publication )

Cell Death Differ, 2018, 25(12):2053-2070

PubMed: 29515255 ( click the link to review the publication )

Sci Signal, 2018, 11(557)

PubMed: 30459283 ( click the link to review the publication )

Cell Death Dis, 2018, 9(3):262

PubMed: 29449529 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(11-:2271-2284

PubMed: 30135214 ( click the link to review the publication )
Mol Cancer Ther, 2018, 17(12):2622-2632

PubMed: 30282811 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(5):931-942

PubMed: 29440449 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(1):222-231

PubMed: 29054983 ( click the link to review the publication )

Am J Cancer Res, 2018, 8(1):183-191

PubMed: 29416931 ( click the link to review the publication )

Mol Pharm, 2018, 15(5):1892-1900

PubMed: 29595984 ( click the link to review the publication )

Front Oncol, 2018, 8:460

PubMed: 30464927 ( click the link to review the publication )

Cancer Gene Ther, 2018, 26(1-2):1-10

PubMed: 29925897 ( click the link to review the publication )

Cancer Discov, 2018, 8(6):714-729

PubMed: 29650534 ( click the link to review the publication )

Am J Cancer Res, 2018, 8(8):1541-1550

PubMed: 30210922 ( click the link to review the publication )

J Proteome Res, 2018, 17(1):63-75

PubMed: 29164889 ( click the link to review the publication )

Cancer Commun (Lond), 2018, 38(1):19

PubMed: 29764505 ( click the link to review the publication )

Cancer Res Treat, 2018, 50(2):599-613

PubMed: 28675026 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2018, 82(2):251-263

PubMed: 29855693 ( click the link to review the publication )

Pediatr Blood Cancer, 2018, 65(8):e27094

PubMed: 29697184 ( click the link to review the publication )

Oncol Lett, 2018, 16(5):5983-5991

PubMed: 30333869 ( click the link to review the publication )

Oncol Lett, 2018, 16(5):5992-5996

PubMed: 30333870 ( click the link to review the publication )

Oncotarget, 2018, 9(43-:27242-27255

PubMed: 29930762 ( click the link to review the publication )

Oncolytic Virother, 2018, 7:107-116

PubMed: 30538967 ( click the link to review the publication )

J Thorac Oncol, 2017, S1556-0864(17)30365-9

PubMed: 28502721 ( click the link to review the publication )

Cancer Res, 2017, 77(13):3551-3563

PubMed: 28428274 ( click the link to review the publication )

Cancer Res, 2017, 77(13):3502-3512

PubMed: 28512244 ( click the link to review the publication )

Cell Rep, 2017, 21(11):3298-3309

PubMed: 29241554 ( click the link to review the publication )

J Pathol, 2017, 243(3):307-319

PubMed: 28741662 ( click the link to review the publication )

Cell Death Dis, 2017, 8(8):e3013

PubMed: 28837150 ( click the link to review the publication )
Br J Cancer, 2017, 117(12):1787-1797

PubMed: 29024938 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(10):2234-2245

PubMed: 28729401 ( click the link to review the publication )

Oncologist, 2017, 22(2):158-164

PubMed: 28167572 ( click the link to review the publication )

Sci Rep, 2017, 7:44206

PubMed: 28287179 ( click the link to review the publication )

Am J Cancer Res, 2017, 7(2):203-217

PubMed: 28337371 ( click the link to review the publication )

BMC Cancer, 2017, 17(1):191

PubMed: 28292264 ( click the link to review the publication )

Molecules, 2017, 22(12)

PubMed: 29206199 ( click the link to review the publication )

Medchemcomm, 2017, 8(10):1914-1918

PubMed: 30108712 ( click the link to review the publication )

Oncol Lett, 2017, 13(6):4085-4092

PubMed: 28599410 ( click the link to review the publication )

Cardiooncology, 2017, 3

PubMed: 28217366 ( click the link to review the publication )

Oncotarget, 2017, 8(70):114945-114955

PubMed: 29383132 ( click the link to review the publication )

Oncotarget, 2017, 8(35):58771-58780

PubMed: 28938595 ( click the link to review the publication )

Oncotarget, 2017, 8(31):51675-51687

PubMed: 28881678 ( click the link to review the publication )

Blood, 2016, 128(9):1234-45

PubMed: 27297792 ( click the link to review the publication )

Genome Biol, 2016, 17:80

PubMed: 27139883 ( click the link to review the publication )

Nat Commun, 2016, 7:10690

PubMed: 26891683 ( click the link to review the publication )

J Clin Invest, 2016, 3;126(10):3739-3757

PubMed: 27571409 ( click the link to review the publication )

Nat Commun, 2016, 7:11815

PubMed: 27283993 ( click the link to review the publication )

J Thorac Oncol, 2016, 11(8):1273-1281

PubMed: 27068398 ( click the link to review the publication )

Clin Cancer Res, 2016, 22(7):1787-99

PubMed: 26667487 ( click the link to review the publication )

Clin Cancer Res, 2016, 22(22):5527-5538

PubMed: 27780853 ( click the link to review the publication )

Clin Cancer Res, 2016, 22(24):6031-6038

PubMed: 27091406 ( click the link to review the publication )

Cancer Res, 2016, 76(6):1506-16

PubMed: 26719536 ( click the link to review the publication )

Cancer Res, 2016, 76(13):3895-903

PubMed: 27197184 ( click the link to review the publication )
Cancer Res, 2016, 76(4):974-83

PubMed: 26837769 ( click the link to review the publication )

J Pathol, 2016, 238(4):543-9

PubMed: 26606880 ( click the link to review the publication )

Cancer Discov, 2016, 6(12):1334-1341

PubMed: 27694386 ( click the link to review the publication )

Oncoimmunology, 2016, 5(3):e1094598

PubMed: 27141355 ( click the link to review the publication )

Mol Pharm, 2016, 13(11):3724-3735

PubMed: 27653969 ( click the link to review the publication )

Int J Oncol, 2016, 49(6):2453-2463

PubMed: 27748897 ( click the link to review the publication )

Int J Oncol, 2016, 49(6):2236-2244

PubMed: 27748834 ( click the link to review the publication )

Cellular Signalling, 2016, 19;28(6):652-662

PubMed: 27006333 ( click the link to review the publication )

Endocrine, 2016, 53(1):145-56

PubMed: 26370117 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2016, 77(3):623-8

PubMed: 26849637 ( click the link to review the publication )

PLoS One, 2016, 11(11):e0165983

PubMed: 27832137 ( click the link to review the publication )

Vet Parasitol, 2016, 227:64-8

PubMed: 27523939 ( click the link to review the publication )

Int J Surg, 2016, 28:179-84

PubMed: 26957017 ( click the link to review the publication )

World J Clin Oncol, 2016, 7(6):425-432

PubMed: 28008383 ( click the link to review the publication )

Sci Rep, 2016, 10.1038/srep24817

PubMed: 27102549 ( click the link to review the publication )

Oncotarget, 2016, 7(51):84675-84687

PubMed: 27835869 ( click the link to review the publication )

Springerplus, 2016, 5:348

PubMed: 27057482 ( click the link to review the publication )

Sci Rep, 2016, 6:32992

PubMed: 27623107 ( click the link to review the publication )

Tumour Biol, 2016, 37(4):4373-82

PubMed: 26499783 ( click the link to review the publication )

Oncotarget, 2016, 7(46):75968-75980

PubMed: 27732954 ( click the link to review the publication )

Oncotarget, 2016, 7(20):29199-210

PubMed: 27078848 ( click the link to review the publication )

Oncotarget, 2016, 7(18-:25983-6002

PubMed: 27036020 ( click the link to review the publication )

Oncotarget, 2016, 7(17):23715-29

PubMed: 27009859 ( click the link to review the publication )

Blood, 2015, 126(26):2821-31

PubMed: 26531163 ( click the link to review the publication )
Cell Res, 2015, 10.1038/cr.2015.16

PubMed: 25656847 ( click the link to review the publication )

Nat Commun, 2015, 6:7002

PubMed: 25926053 ( click the link to review the publication )

Cancer Res, 2015, 10.1158/0008-5472.CAN-15-0370

PubMed: 25952648 ( click the link to review the publication )

Cancer Res, 2015, 75(14):2916-27

PubMed: 26018086 ( click the link to review the publication )

Oncoimmunology, 2015, 5(3):e1108514

PubMed: 27141364 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(11-:2433-40

PubMed: 26351321 ( click the link to review the publication )

Radiother Oncol, 2015, 114(2):173-81

PubMed: ( click the link to review the publication )

Radiother Oncol, 2015, 114(2):173-81

PubMed: ( click the link to review the publication )

Cancer Sci, 2015, 106(3):244-52

PubMed: 25581823 ( click the link to review the publication )

Lung Cancer, 2015, 90(3):590-7

PubMed: 26547802 ( click the link to review the publication )

J Cell Physiol, 2015, 230(9):2281-98

PubMed: 25704960 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2015, 285(1):51-60

PubMed: 25841593 ( click the link to review the publication )

Int J Oncol, 2015, 46(3):1025-30

PubMed: 25502629 ( click the link to review the publication )

PLoS One, 2015, 10(4):e0124283

PubMed: 25919140 ( click the link to review the publication )

PLoS One, 2015, 10(7):e0132330

PubMed: 26147305 ( click the link to review the publication )

PLoS One, 2015, 10(4):e0121378

PubMed: 25874976 ( click the link to review the publication )

Onco Targets Ther, 2015, 8:375-83

PubMed: 25678804 ( click the link to review the publication )

Biochem Biophys Res Commun, 2015, 10.1016/j.bbrc.2015.02.114

PubMed: 25735977 ( click the link to review the publication )

Oncotarget, 2015, 6(27):24320-32

PubMed: 26172300 ( click the link to review the publication )

Cell, 2015, 162(6):1271-85

PubMed: 26359985 ( click the link to review the publication )

Oncotarget, 2015, 6(37):40268-82

PubMed: 26384345 ( click the link to review the publication )

Zhongguo Fei Ai Za Zhi, 2015, 18(6):330-9

PubMed: 26104888 ( click the link to review the publication )

Oncotarget, 2015, 6(14):11820-32

PubMed: 25909220 ( click the link to review the publication )

Oncotarget, 2015, 6(37):40268-82

PubMed: 26384345 ( click the link to review the publication )
Oncotarget, 2015, 6(30):28774-89

PubMed: 26299615 ( click the link to review the publication )

J Thorac Oncol, 2014, 9(11):1638-46

PubMed: 25144242 ( click the link to review the publication )

J Thorac Oncol, 2014, 9(11):1638-46

PubMed: ( click the link to review the publication )

J Thorac Oncol, 2014, 9(6):775-83

PubMed: 24828661 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(11):2898-909

PubMed: 24714777 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(18):4806-15

PubMed: 25052479 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2014, 111(44):E4706-15

PubMed: 25331893 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(11):2898-909

PubMed: 24714777 ( click the link to review the publication )

Cell Rep, 2014, 8(4):1037-48

PubMed: 25127139 ( click the link to review the publication )

Elife, 2014, 10.7554/eLife.03751

PubMed: 25551293 ( click the link to review the publication )

Cancer Lett, 2014, 351(2):215-21

PubMed: 24887559 ( click the link to review the publication )

Mol Cancer Ther, 2014, 13(1):134-43

PubMed: 24170771 ( click the link to review the publication )

Mol Cancer Ther, 2014, 10.1158/1535-7163.MCT-14-0274

PubMed: 25349307 ( click the link to review the publication )

Mol Oncol, 2014, 9(1):260-9

PubMed: 25226813 ( click the link to review the publication )

Gastric Cancer, 2014, 10.1007/s10120-014-0444-1

PubMed: 25407459 ( click the link to review the publication )

Cancer Sci, 2014, 105(5):528-36

PubMed: 24612061 ( click the link to review the publication )

Cell Cycle, 2014, 13(24):3808-17

PubMed: 25426675 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2014, 140(4):589-98

PubMed: 24509625 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2014, 74(5):1023-8

PubMed: 25205428 ( click the link to review the publication )

PLoS One, 2014, 9(11):e112148

PubMed: 25386922 ( click the link to review the publication )

PLoS One, 2014, 9(9):e105919

PubMed: 25221930 ( click the link to review the publication )

Biomed Res Int, 2014, 2014:764981

PubMed: 25057499 ( click the link to review the publication )

Biochem Biophy Res Co, 2014, 10.1016/j.bbrc.2014.10.126

PubMed: ( click the link to review the publication )

Jpn J Clin Oncol, 2014, 44(10):963-8

PubMed: 25170107 ( click the link to review the publication )
Future Oncol, 2014, 10(2):211-7

PubMed: 24490607 ( click the link to review the publication )

Leuk Res, 2014, 38(4):503-8

PubMed: 24486291 ( click the link to review the publication )

Korean J Parasitol, 2014, 52(4):439-41

PubMed: 25246725 ( click the link to review the publication )

Oncotarget, 2014, 5(13):4920-8

PubMed: 24952482 ( click the link to review the publication )

Urol Oncol, 2014, 32(6):877-84

PubMed: 24929890 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(9):2584-91

PubMed: 23515407 ( click the link to review the publication )

Int J Cancer, 2013, 133(2):427-36

PubMed: 23335077 ( click the link to review the publication )

Int J Cancer, 2013, 132(2):E74-84

PubMed: 22948846 ( click the link to review the publication )

Br J Cancer, 2013, 109(12):3084-91

PubMed: 24149177 ( click the link to review the publication )

Exp Mol Med, 2013, 45:e64

PubMed: 24263233 ( click the link to review the publication )

Mol Oncol, 2013, 7(6):1093-102

PubMed: 23993685 ( click the link to review the publication )

ACS Chem Biol, 2013, 9(3):777-84

PubMed: 24397822 ( click the link to review the publication )

J Am Heart Assoc, 2013, 2(6):e000376

PubMed: 24308935 ( click the link to review the publication )

Cancer Sci, 2013, 104(12):1640-6

PubMed: 24118504 ( click the link to review the publication )

Cancer Sci, 2013, 104(12):1618-25

PubMed: 24112719 ( click the link to review the publication )

Sci Rep, 2013, 3:3450

PubMed: 24356251 ( click the link to review the publication )

Int J Cardiol, 2013, 168(4):3486-94

PubMed: 23680593 ( click the link to review the publication )

Mol Pharmacol, 2013, 83(4):882-93

PubMed: 23371912 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2013, 272(1):245-55

PubMed: 23707608 ( click the link to review the publication )

J Cell Biochem, 2013, 114(4):816-22

PubMed: 23060267 ( click the link to review the publication )

Molecules, 2013, 18(12):15412-21

PubMed: 24335618 ( click the link to review the publication )

PLoS One, 2013, 8(12):e82236

PubMed: 24349229 ( click the link to review the publication )

PLoS One, 2013, 8(12):e84700

PubMed: 24386407 ( click the link to review the publication )

PLoS One, 2013, 8(2):e56010

PubMed: 23418494 ( click the link to review the publication )
Tumour Biol, 2013, 35(4):3229-35

PubMed: 24293393 ( click the link to review the publication )

Springerplus, 2013, 2:497

PubMed: 24102046 ( click the link to review the publication )

CELON PHARMA, 2013, 2013

PubMed: ( click the link to review the publication )

Sci Transl Med, 2012, 4(120):120ra17

PubMed: 22277784 ( click the link to review the publication )

Br J Pharmacol, 2012, 166(5):1669-83

PubMed: 22233293 ( click the link to review the publication )

Neoplasia, 2012, 14(7):572-84

PubMed: 22904675 ( click the link to review the publication )

ACS Chem Biol, 2012, 7(8):1429-35

PubMed: 22625864 ( click the link to review the publication )

J Biol Chem, 2012, 287(18):14586-97

PubMed: 22418436 ( click the link to review the publication )

J Biol Chem, 2012, 287(47):39812-23

PubMed: 23024367 ( click the link to review the publication )

PLoS One, 2012, 7(2):e30820

PubMed: 22319590 ( click the link to review the publication )

Pediatr Blood Cancer, 2012, 17(23):7394-401

PubMed: 22488797 ( click the link to review the publication )

Clin Cancer Res, 2011, 59(3):440-7

PubMed: 21948233 ( click the link to review the publication )

Cancer Res, 2011, 71(15):5255-64

PubMed: 21697284 ( click the link to review the publication )

J Biomol Screen, 2011, 16(2):141-54

PubMed: 21297102 ( click the link to review the publication )

Int J Proteomics, 2011, 2011:215496

PubMed: 22091388 ( click the link to review the publication )

产品安全说明书

c-Met抑制剂选择性比较

生物活性

产品描述

靶点

ROS1 ^[6] (Cell-free assay)	c-Met ^[1] (A549, MDA-MB-231, GTL-16, HT29, 786-O, Colo-205, A498 cells)	ALK ^[1] (Karpas299 cells)
<0.025 nM(Ki)	11 nM	24 nM

体外研究

PF-2341066作用于mIMCD3小鼠和MDCK犬上皮细胞，作用于c-Met磷酸化作用时具有相似效果，IC50分别为5 nM 和20 nM。PF-2341066作用于表达c-Met ATP-结合位点突变型V1092I 或H1094R或 P-环突变 M1250T 的NIH3T3 细胞，具有相似的活性，且活力增高，IC50分别为19 nM,2 nM 和15 nM,而作用于表达野生型受体的NIH3T3 细胞时，IC50为13 nM。^[1] 相反, 观察到PF-2341066作用于表达c-Met活化环突变型Y1230C 和Y1235D的细胞时，与作用于野生型受体相比，效果发生显著改变，IC50分别为127 nM 和92 nM。PF-2341066 作用于分别表达内源性c-Met 突变体R988C和 T1010I 的NCI-H69 和HOP92 细胞，也有效抑制c-Met 磷酸化, IC50分别为13 nM 和16 nM。与作用于c-Met相比，PF-2341066作用于VEGFR2 和PDGFRβ RTKs, 选择性高1000多倍，作用于IRK和Lck选择性高250多倍，作用于Tie2, TrkA,和TrkB选择性高40到60倍。PF-2341066 作用于RON和 Axl RTKs时选择性为20到30倍。相反，PF-2341066 作用于表达ALK RTK 的核磷蛋白 (NPM)- 间变性淋巴瘤激酶(ALK) 致癌融合突变体和 KARPAS299人间变性大细胞淋巴瘤(ALCL)细胞系时具有相近的IC50值，为24 nM。PF-2341066抑制c-Met依赖的癌细胞的肿瘤表现型，和内皮细胞的血管生成表现型。PF-2341066抑制人GTL-16胃癌细胞生长，IC50为9.7 nM。PF-2341066诱导 GTL-16细胞凋亡，IC50 为8.4 nM。PF-2341066 抑制HGF刺激的人NCI-H441肺癌细胞迁移和入侵，IC50分别为11 nM 和6.1 nM。PF-2341066抑制 MDCK细胞散射，IC50为16 nM。PF-2341066 抑制HGF-刺激的c-Met磷酸化,细胞存活，和Matrigel入侵，IC50分别为11 nM, 14 nM和35 nM。此外, PF-2341066抑制纤维蛋白胶中的血清刺激的 HMVEC分支小管形成 (形成血管)。^[1] PF-2341066 作用于Karpas299 或SU-DHL-1 ALCL细胞，也有效抑制 NPM-ALK磷酸化，IC50 为24 nM。PF-2341066 有效抑制细胞增殖，伴随着使细胞周期停在G(1)-S期，且诱导 ALK阳性的 ALCL 细胞凋亡，IC50为30 nM, 但是作用于ALK阴性的淋巴瘤细胞则无效果。 ^[2] 此外, PF-2341066 抑制骨肉瘤的一些活动行为，及其肿瘤生长 (例如,增殖和存活)和转移 (例如，入侵和形成克隆)。^[3]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
BAF3	NIH6dXVEgXSxdH;4bYMhSXO\|YYm=		NXTtb\|dYPDhiaB?=	NG\FfWlFVVOR	MmS5R5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmFHOyClZXzsd{BmgHC{ZYPzbY5oKEGOSzDGNVE4PExibYX0ZY51KGOxZYjwdoV{e2mwZzDFUWw1KHerdHigTWM2OCCxZjCwMlYzKM7:TR?=	M3WwfFIyPTd{NUi5
BAF3	M2PrcWN6fG:2b4jpZ{BCe3OjeR?=		MYW0PEBp	NGDOR4tFVVOR	NW\aWGU{S3m2b4TvfIlkcXS7IHHnZYlve3RibX;1d4UhSkGIMzDj[YxteyCneIDy[ZN{cW6pIFHMT{BNOTF7Nl2gcZV1[W62IHPv[ZhxemW\|c3nu[{BGVUx2IIfpeIghUUN3MDDv[kAzNjJizszN	NFfqc4gzOTV5MkW4PS=>
BAF3	Mnz6R5l1d3SxeHnjJGF{e2G7		M{DFVVQ5KGh?	M4LHfWROW09?	NVf6eGF{S3m2b4TvfIlkcXS7IHHnZYlve3RibX;1d4UhSkGIMzDj[YxteyCneIDy[ZN{cW6pIFXNUFQuSUyNIIfpeIghUUN3MDDv[kAxNjJ6IN88US=>	MV6yNVU4OjV6OR?=
Kelly	MojVR5l1d3SxeHnjJGF{e2G7			MUTEUXNQ	M4r2T2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGtmdGy7IHPlcIx{KGW6cILld5NqdmdiQVzLJGYyOTd2TDDteZRidnRid3n0bEBKSzVyIH;mJFAvPDJizszN	Ml7JNlE2PzJ3OEm=
SH-SY5Y	MlHIR5l1d3SxeHnjJGF{e2G7			MmPYSG1UVw>?	MXzDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDTTE1UYTW\IHPlcIx{KGW6cILld5NqdmdiQVzLJGYyOTd2TDDteZRidnRid3n0bEBKSzVyIH;mJFAvPTNizszN	MoHQNlE2PzJ3OEm=
SMS-KCN	Mln4R5l1d3SxeHnjJGF{e2G7			M3LsZmROW09?	Ml;BR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gV21UNUuFTjDj[YxteyCneIDy[ZN{cW6pIFHMT{BTOTJ5NWGgcZV1[W62IIfpeIghUUN3MDDv[kAxNjlzIN88US=>	Mn7FNlE2PzJ3OEm=
BAF3	M2XjNGN6fG:2b4jpZ{BCe3OjeR?=		NV7Ue3VvPDhiaB?=	NYPqXJFqTE2VTx?=	Mk\oR5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmFHOyClZXzsd{BmgHC{ZYPzbY5oKFSnbD3BUGshf2m2aDDJR\|UxKG:oIECuNVkh\|ryP	NWfIeGVKOjF3N{K1PFk>
3T3	NYfEXFh4TnWwY4Tpc44hSXO\|YYm=		NWnzdHV4OSCq	MYDEUXNQ	NFnUT4FKdmirYnn0bY9vKG:oIGLPUkBie3Onc4Pl[EBieyCpcn;3eIgh\mGldH;yMYlv\HWlZXSgZZV1d3Cqb4PwbI9zgWyjdHnvckB4cXSqIFnDOVAhd2ZiMD6wPEDPxE1?	MmWzNlE5OTJ2MUS=
3T3-E	MmnQSpVv[3Srb36gRZN{[Xl?		Mmm4NUBp	NVG2OZVUTE2VTx?=	NFPvSYZKdmirYnn0bY9vKG:oIGTJSVIh[XO\|ZYPz[YQh\3Kxd4ToJIZi[3Sxcj3pcoR2[2WmIHH1eI9xcG:\|cHjvdplt[XSrb36ge4l1cCCLQ{WwJI9nKDBwNES4JO69VQ>?	MWCyNVgyOjRzNB?=
A549	NYXvfWRLU2mwYYPlJGF{e2G7		MYixJIg>	MmTISG1UVw>?	MV3Jcohq[mm2aX;uJI9nKGi3bXHuJJJm[2:vYnnuZY51KGNvTVXUJItqdmG\|ZTDlfJBz\XO\|ZXSgZZN{\XO\|ZXSgZZMhcW6qaXLpeIlwdiCxZjDIS2YucW6mdXPl[EBifXSxcHjvd5Bpd3K7bHH0bY9vKHerdHigTWM2OCCxZjCwMlAxQCEQvF2=	NWXXToNMOjF6MUK0NVQ>
BAF3-BCL	M13jV2Z2dmO2aX;uJGF{e2G7		NHPKSZMyKGh?	NW[xd2I2TE2VTx?=	NXWxU\|hoUW6qaXLpeIlwdiCxZjDBRmwh[XO\|ZYPz[YQh[XNiZ4Lve5RpKG[jY4Tvdk1qdmS3Y3XkJIF2fG:yaH;zdIhwenmuYYTpc44hf2m2aDDJR\|UxKG:oIEGuNVU6KM7:TR?=	M3T5NlIyQDF{NEG0
HEK293	M1zWNmZ2dmO2aX;uJGF{e2G7		M2TCTFEhcA>?	NVjXW\|dYTE2VTx?=	MlHSTY5pcWKrdHnvckBw\iCDWFygZZN{\XO\|ZXSgZZMh\3Kxd4ToJIZi[3Sxcj3pcoR2[2WmIHH1eI9xcG:\|cHjvdplt[XSrb36ge4l1cCCLQ{WwJI9nKDBwMkm0JO69VQ>?	NID1UJgzOThzMkSxOC=>
HEK293	MnPHSpVv[3Srb36gRZN{[Xl?		MWCxJIg>	NUPsOXhITE2VTx?=	NGjpc3ZKdmirYnn0bY9vKG:oIFnSJIF{e2W\|c3XkJIF{KGe{b4f0bEBn[WO2b4KtbY5lfWOnZDDheZRweGixc4Doc5J6dGG2aX;uJJdqfGhiSVO1NEBw\iB{Lki4O{DPxE1?	M4XXO\|IyQDF{NEG0
Jurkat	MkjxSpVv[3Srb36gRZN{[Xl?		NV:wcFUyOSCq	M3e3fmROW09?	NV\MU5JJUW6qaXLpeIlwdiCxZjDMR2sh[XO\|ZYPz[YQh[XNiZ4Lve5RpKG[jY4Tvdk1qdmS3Y3XkJIF2fG:yaH;zdIhwenmuYYTpc44hf2m2aDDJR\|UxKG:oIEKuO\|QyKM7:TR?=	M2L0fVIyQDF{NEG0
KARPAS299	MXzLbY5ie2ViQYPzZZk>		NVLRRpBNOSCq	NIfHflNFVVOR	NUXFfHp6UW6qaXLpeIlwdiCxZjDBUGsh[XO\|ZYPz[YQh[XNiZ4Lve5RpKG[jY4Tvdk1qdmS3Y3XkJIF2fG:yaH;zdIhwenmuYYTpc44hf2m2aDDJR\|UxKG:oIECuNFIh\|ryP	M4PmdFIyQDF{NEG0
PAE	NX7xbG9[TnWwY4Tpc44hSXO\|YYm=		NFHQb3kyKGh?	Mm\MSG1UVw>?	NEPSbm9KdmirYnn0bY9vKG:oIGTST2Ih[XO\|ZYPz[YQh[XNiZ4Lve5RpKG[jY4Tvdk1qdmS3Y3XkJIF2fG:yaH;zdIhwenmuYYTpc44hf2m2aDDJR\|UxKG:oIECuN\|k6KM7:TR?=	M{fhZVIyQDF{NEG0
BAF3	MlHFSpVv[3Srb36gRZN{[Xl?		NWDCSoR7Oi1\|IHS=	MnPnSG1UVw>?	NWXYNlFyUW6qaXLpeIlwdiCxZjDUSWwu\nW\|ZXSgbY5{fWyrbjDy[YNmeHSxcjDlfJBz\XO\|ZXSge4l1cCCLQ{WwJI9nKDFwNkSzJO69VQ>?	MXKyN\|c1OjJ3Mh?=
KARPAS299	M3HNTmN6fG:2b4jpZ{BCe3OjeR?=		MmG2Nk0{KGR?	NEjOOG5FVVOR	MUnJR\|UxRTBwME[0NkDPxE1?	NELoN4kzOzd2MkK1Ni=>
EBC1	NXnseW5vT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MYi3NkBp	MYTEUXNQ	MmW0TWM2OD1yLkCyN{DPxE1?	NHXCT4EzOzl7M{OyPC=>
HCT116	NG\vOXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NVHxOmVKPzJiaB?=	NVrPOpI2TE2VTx?=	MlnBTWM2OD1zND64NkDPxE1?	M1ewZVI{QTl\|M{K4
MCF7	MoTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MkHHO\|IhcA>?	NGnXeXVFVVOR	MmezTWM2OD17LkW4JO69VQ>?	MmnzNlM6QTN\|Mki=
MDA-MB-231	NHPr[ItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NWD6[HlWPzJiaB?=	NXnDUG9ZTE2VTx?=	NXXZWJZwUUN3ME2xNE45KM7:TR?=	M1vyXlI{QTl\|M{K4
MKN45	M1vSNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M4rGflczKGh?	NHPVc2lFVVOR	NWPEXZRyUUN3ME2wMlAyOyEQvF2=	NGPXbWIzOzl7M{OyPC=>
NCI-H441	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NXfjfFlLPzJiaB?=	Ml3jSG1UVw>?	NUTE[3ZPUUN3ME2xO{4zPSEQvF2=	M1fPZlI{QTl\|M{K4
NCI-H661	NI\MSo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NXrmcGV6PzJiaB?=	NGqzclBFVVOR	M4PwVWlEPTB;MUGuOFch\|ryP	NX\0NVV2OjN7OUOzNlg>
SK-MEL-28	NWTmZVJtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NGDwe444OiCq	MnvMSG1UVw>?	MXHJR\|UxRTFyLkm3JO69VQ>?	MViyN\|k6OzN{OB?=
SKOV3	MkizS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NH61TGo4OiCq	NWmxUIo4TE2VTx?=	M1:1W2lEPTB;MUKuPFUh\|ryP	NUjXTVBGOjN7OUOzNlg>
SNU5	MlfQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NIrKUnk4OiCq	MlnKSG1UVw>?	NHzIUIxKSzVyPUCuNFE3KM7:TR?=	M3PSTVI{QTl\|M{K4
NCI-H2228	NEHNSItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NWrw[m5tPzJiaB?=	MXXEUXNQ	NYTGXplRUW6qaXLpeIlwdiCxZjDBUGsu\nW\|aX;uJIRzcX[nbjDj[YxtKHC{b3zp[oVz[XSrb36ge4l1cCCLQ{WwJI9nKDBwMUG4JO69VQ>?	MnvpNlQ1OzJ7MEm=
NCI-H3122	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MmLGO\|IhcA>?	MX\EUXNQ	M3vGd2lvcGmkaYTpc44hd2ZiQVzLMYZ2e2mxbjDkdol3\W5iY3XscEBxem:uaX\ldoF1cW:wIIfpeIghUUN3MDDv[kAxNjFyODFOwG0>	MoDRNlQ1OzJ7MEm=
NCI-H3122	MmmyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M4DRUVczKGh?	NXLjNWd4TE2VTx?=	MnTvTY5pcWKrdHnvckBw\iCDTFut[pV{cW:wIHTybZZmdiClZXzsJJBzd2yrZnXyZZRqd25iaX6gbJVu[W5iTlPJMWg{OTJ{IHPlcIx{KGijcnLvdolv\yCDTFugS\|EzPjmDIH31eIFvfCC5aYToJGlEPTBib3[gNE43OjNizszN	NEDmb3AzPDR\|MkmwPS=>
NCI-H3122	NV;aUWpmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MUe3NkBp	NXnDWVE3TE2VTx?=	MmDYTY5pcWKrdHnvckBw\iCDTFut[pV{cW:wIHTybZZmdiClZXzsJJBzd2yrZnXyZZRqd25iaX6gbJVu[W5iTlPJMWg{OTJ{IHPlcIx{KGijcnLvdolv\yCDTFugUFEyQT[PIH31eIFvfCC5aYToJGlEPTBib3[gNE45OzhizszN	NVT5[mdIOjR2M{K5NFk>
NIH-3T3	M3G2cGtqdmG\|ZTDBd5NigQ>?		MX[xJIg>	MmHrSG1UVw>?	MY\Jcohq[mm2aX;uJI9nKGi3bXHuJJdqdGRidInw[UBGVUx2LX\1d4VlKEGOSzDlfJBz\XO\|ZXSgZZN{\XO\|ZXSgZZMheGixc4Doc5J6dGG2ZXSgRWxMKGyndnXsJJdqfGhiSVO1NEBw\iByLkC4JO69VQ>?	MmK3NlQ1OzJ7MEm=
NIH-3T3	NH7DW\|NMcW6jc3WgRZN{[Xl?		NIXhfngyKGh?	NFfmW\|dFVVOR	MY\Jcohq[mm2aX;uJI9nKGi3bXHuJGVOVDRvZoXz[YQhSUyNIFexNlY6SSCvdYThcpQh\XiycnXzd4VlKGG\|c3Xzd4VlKGG\|IIDoc5NxcG9vQVzLJIxmfmWuIIfpeIghUUN3MDDv[kAxNjZyNTFOwG0>	NViwe4J3OjR2M{K5NFk>
NIH-3T3	NH\WXINMcW6jc3WgRZN{[Xl?		M1TDN\|EhcA>?	MmPtSG1UVw>?	MYHJcohq[mm2aX;uJI9nKGi3bXHuJGVOVDRvZoXz[YQhSUyNIGOxNlA3YSCvdYThcpQh\XiycnXzd4VlKGG\|c3Xzd4VlKGG\|IIDoc5NxcG9vQVzLJIxmfmWuIIfpeIghUUN3MDDv[kAxNjZ{NjFOwG0>	M4TGTlI1PDN{OUC5
NIH-3T3	MmTiT4lv[XOnIFHzd4F6		MmnmNUBp	M3rJcmROW09?	NF3CSGZKdmirYnn0bY9vKG:oIHj1cYFvKEWPTESt[pV{\WRiQVzLJGwyOTl4TTDteZRidnRiZYjwdoV{e2WmIHHzd4V{e2WmIHHzJJBpd3OyaH:tRWxMKGyndnXsJJdqfGhiSVO1NEBw\iByLki0N{DPxE1?	NHXVOXgzPDR\|MkmwPS=>
NIH-3T3	NGSxbYlMcW6jc3WgRZN{[Xl?		MXuxJIg>	NVPzZYlUTE2VTx?=	MmnTTY5pcWKrdHnvckBw\iCqdX3hckBGVUx2LX\1d4VlKEGOSzDMNVE2OlJibYX0ZY51KGW6cILld5Nm\CCjc4Pld5Nm\CCjczDwbI9{eGixLVHMT{Bt\X[nbDD3bZRpKEmFNUCgc4YhOS5yMk[g{txO	M4\TclI1PDN{OUC5
BAF3	M1ToVGZ2dmO2aX;uJGF{e2G7		MX23NkBp	MWrEUXNQ	M2G3U2lvcGmkaYTpc44hd2ZiTmDNM2FNUyC2cnHud4Zm[3SnZDDhd5Nme3OnZDDhd{Bk\WyuIHfyc5d1cCCrbnjpZol1cW:wIIfpeIghUUN3MDDv[kAxNjB3MTFOwG0>	MojJNlQ1Pjh4M{K=
BAF3	MmnBR5l1d3SxeHnjJGF{e2G7		MYK3NkBp	MlvDSG1UVw>?	Ml\CTWM2OD1yLkm4JO69VQ>?	NW\R[\|BHOjR2Nki2N\|I>
NIH-3T3	MWfLbY5ie2ViQYPzZZk>		M2PU[FEhcA>?		Mkm1TY5pcWKrdHnvckBw\iCqdX3hckBGVUx2LX\1d4VlKEGOSzDGNVE4PExibYX0ZY51KGW6cILld5Nm\CCjc4Pld5Nm\CCjczDwbI9{eGixLVHMT{Bt\X[nbDD3bZRpKEmFNUCgc4YhOC5zNkWg{txO	MkP4NlQ5OTlzMU[=
NIH-3T3	MlPtT4lv[XOnIFHzd4F6		MWKxJIg>		M1j4VmlvcGmkaYTpc44hd2ZiaIXtZY4hTU2OND3meZNm\CCDTFugR\|EyPT[\IH31eIFvfCCneIDy[ZN{\WRiYYPz[ZN{\WRiYYOgdIhwe3Cqbz3BUGshdGW4ZXyge4l1cCCLQ{WwJI9nKDBwNEe4JO69VQ>?	NXjscmd{OjR6MUmxNVY>
NIH-3T3	NIXPR4NMcW6jc3WgRZN{[Xl?		NEDVPHkyKGh?		NYSyVXpUUW6qaXLpeIlwdiCxZjDoeY1idiCHTVy0MYZ2e2WmIFHMT{BIOTJyMmKgcZV1[W62IHX4dJJme3OnZDDhd5Nme3OnZDDhd{BxcG:\|cHjvMWFNUyCuZY\lcEB4cXSqIFnDOVAhd2ZiMT6xOFgh\|ryP	M{TWNFI1QDF7MUG2
NIH-3T3	M{Dm[WtqdmG\|ZTDBd5NigQ>?		MlLENUBp		NFTPdnVKdmirYnn0bY9vKG:oIHj1cYFvKEWPTESt[pV{\WRiQVzLJFEyPTGWaX7zJI12fGGwdDDlfJBz\XO\|ZXSgZZN{\XO\|ZXSgZZMheGixc4Doc{1CVEtibHX2[Ywhf2m2aDDJR\|UxKG:oIEOuNFM6KM7:TR?=	NW\r[ox3OjR6MUmxNVY>
KARPAS299	NEfqSnJMcW6jc3WgRZN{[Xl?		M4e3eVkxKG2rbh?=	NUjNdph{TE2VTx?=	MoS3TY5pcWKrdHnvckBw\iCQUF2t[pV{\WRiQVzLJJBpd3OyaH;yfYxifGmxbjDlfJBz\XO\|ZXSge4l1cCCLQ{WwJI9nKDBwMUGg{txO	MonoNlQ6ODB5NUC=
MKN 45	MWjLbY5ie2ViQYPzZZk>		NYjicIk2OSCq	Mn\wSG1UVw>?	MUnJcohq[mm2aX;uJI9nKGNvTXX0JJBpd3OyaH;yfYxifGmxbjD3bZRpKEmFNUCgc4YhOC5yMjFOwG0>	Mn;mNlQ6ODB5NUC=
A549	MVTDfZRwfG:6aXOgRZN{[Xl?		NWj0[Yg{PDhiaB?=	MUHEUXNQ	NU\pdppVUUN3MDDv[kA1NjB6NDFOwG0>	NEjtRYgzPDlyMEizNC=>
NCI-H1975	M3v5NmN6fG:2b4jpZ{BCe3OjeR?=		NIfqRnM1QCCq	Ml\2SG1UVw>?	M1O4[WlEPTBib3[gO{42PTFizszN	MXmyOFkxODh\|MB?=
NCI-H1993	MYnDfZRwfG:6aXOgRZN{[Xl?		MYC0PEBp	MVLEUXNQ	NIG5SWFKSzVyIH;mJFAvODZzIN88US=>	MnWzNlQ6ODB6M{C=
NCI-H1993	NY\ac29HSXCxdH;zbZMhSXO\|YYm=	M1PITVEh\|ryP	NFzvPVIzPCCq	NEfEb\|FFVVOR	M4PSS4Rw\XNibn;0JIlv\HWlZTDhdI9xfG:\|aYO=	MoP1NlQ6ODB6M{C=
NIH-3T3	NUe1SpNKS3m2b4TvfIlkKEG\|c3H5		NWTz[m84PDhiaB?=	MV7EUXNQ	NXnaOXRRUUN3MDDv[kAxNjN4NDFOwG0>	M3K0TlI1QTByOEOw
EBC1	NYXRemVkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NIP0bXA4OiCq	M1PSV2ROW09?	MV7JR\|UxKG:oIECuNFA3QSEQvF2=	NWLhXm85OjR7MEC4N\|E>
KARPAS299	NELsfXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NFvTbpU4OiCq	MU\EUXNQ	MXfJR\|UxKG:oIECuNkDPxE1?	M4Cyc\|I1QTByOEOx
NB1	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVK0copMUUN3ME25NU46QCCwTR?=	MoHYV2FPT0WU
NCI-SNU-5	MoKxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYTJR\|UxRTFyNT63OUBvVQ>?	MV;TRW5ITVJ?
SR	NWe5SJpQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX3JR\|UxRTF{Nj6zNUBvVQ>?	MUjTRW5ITVJ?
SF539	NXLrdJhoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1Xib2lEPTB;MkC0MlI1KG6P	MlnQV2FPT0WU
SU-DHL-1	MofmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoSxTWM2OD1\|M{[uPFIhdk1?	NX3N[Ip3W0GQR1XS
SCC-3	MlO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUjYRnBQUUN3ME2zOVYvPzZibl2=	M1PqfHNCVkeHUh?=
DEL	NYr1Zm1CT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVXJR\|UxRTN4OT65JI5O	NXfvZ5o5W0GQR1XS
CTV-1	MlHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlLaTWM2OD13OU[uOFghdk1?	NUjL[pRiW0GQR1XS
EM-2	M17zSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUTNTFhIUUN3ME22NFEvOzRibl2=	MmDxV2FPT0WU
MHH-CALL-2	M3TCZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHPrNlVKSzVyPU[4Nk42PyCwTR?=	NGrTXY1USU6JRWK=
KM12	NITm[49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoHJTWM2OD15ME[uPUBvVQ>?	M362NnNCVkeHUh?=
KINGS-1	M4PFWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHX0UGJKSzVyPUe0PU44PSCwTR?=	M1nLS3NCVkeHUh?=
MEG-01	MnKyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHq1OXNKSzVyPUi1O{43PiCwTR?=	NWHBWHY1W0GQR1XS
BV-173	M{nBNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFrBWZlKSzVyPUGuNFU6QTdizszN	NInidm9USU6JRWK=
LAMA-84	M4q0Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2HDNGlEPTB;MT6zPFI5OiEQvF2=	MWrTRW5ITVJ?
KARPAS-299	NH61RoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV;NRVhRUUN3ME2xMlQxQDZzIN88US=>	Mo\RV2FPT0WU
K-562	NXL5RXFjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnzmTWM2OD1zLkeyNlY6KM7:TR?=	NXXzbZd1W0GQR1XS
SK-LMS-1	M2jqWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWnUV4ZOUUN3ME2xMlc3QDZ5IN88US=>	MnzUV2FPT0WU
MOLT-16	NHvoW4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWXJR\|UxRTFwOUW1O\|Uh\|ryP	MnXHV2FPT0WU
CMK	NETwd\|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYXJR\|UxRTFwOU[xOVkh\|ryP	NF3aVXlUSU6JRWK=
ST486	MoGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGfRenZKSzVyPUKuOFMxPzNizszN	M1f2bnNCVkeHUh?=
CI-1	NXHKVmlNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NITBRoVKSzVyPUKuOFk3PTlizszN	NHW5eI1USU6JRWK=
KP-N-RT-BM-1	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFG1S45KSzVyPUKuO\|AyOjJizszN	NYPpT\|BiW0GQR1XS
ALL-PO	NEDsR4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX7JR\|UxRTNwMUiyNFch\|ryP	NWXpXppqW0GQR1XS
KS-1	MlT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV\JR\|UxRTNwMkGyNlUh\|ryP	M4PR[nNCVkeHUh?=
Becker	MknnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVTJR\|UxRTRwMkO5N{DPxE1?	M4HS[3NCVkeHUh?=
GDM-1	M3TtZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mnq4TWM2OD12LkK0OlE4KM7:TR?=	MUfTRW5ITVJ?
BC-1	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Moe0TWM2OD12LkS5Nlc4KM7:TR?=	NVPhbVExW0GQR1XS
NB14	NXT3VZY2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF;2b4RKSzVyPUSuPFM2OjRizszN	MUXTRW5ITVJ?
NOS-1	M1rZfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGXXe5VKSzVyPUWuN\|M5PzRizszN	NWPC[JVmW0GQR1XS
MZ1-PC	NEmwPHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIDPbmFKSzVyPUWuPFIyPTFizszN	NVKyfGZYW0GQR1XS
A498	MlLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX25dVlMUUN3ME22MlA5PDd\|IN88US=>	NF6zVXpUSU6JRWK=
EW-16	MmHNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnnDTWM2OD14LkO3O\|c{KM7:TR?=	MlLwV2FPT0WU
NALM-6	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGD5fopKSzVyPU[uOlg{QDdizszN	NWXqVmdpW0GQR1XS
EB-3	MmLzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkXaTWM2OD15LkC3NlM{KM7:TR?=	M2LtRnNCVkeHUh?=
697	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFPiRotKSzVyPUmuNlQ{OjlizszN	M2X6b3NCVkeHUh?=
Ramos-2G6-4C10	M3fRXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXvJR\|UxRTlwNUm4OFIh\|ryP	NXXKSVJ5W0GQR1XS
KNS-81-FD	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1ex[GlEPTB;OT62PVY2OyEQvF2=	NGr4[mlUSU6JRWK=
HUTU-80	MoLOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWTyS5FrUUN3ME25Mlc1PjR{IN88US=>	NEXKOVdUSU6JRWK=
LS-411N	NVfyWo5qT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVHqW446UUN3ME2xNE4xPTZ5IN88US=>	NUjJepE5W0GQR1XS
RPMI-8402	Moj1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHnIS2pKSzVyPUGwMlEyPiEQvF2=	NEXNV5JUSU6JRWK=
KU812	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYnPZnpvUUN3ME2xNE4zQTlzIN88US=>	M{fqXXNCVkeHUh?=
EW-1	NVr5[oZQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH;ZfVZKSzVyPUGwMlQ1OjVizszN	NVXEco9uW0GQR1XS
HC-1	NF;mTW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWHFdlhNUUN3ME2xNE41QDR2IN88US=>	MlnRV2FPT0WU
NB69	NEPDbYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlOxTWM2OD1zMD61NFQ{KM7:TR?=	M33aZnNCVkeHUh?=
MFH-ino	NV\Kemh4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NULyVFZFUUN3ME2xNE45OzB\|IN88US=>	M2PhXXNCVkeHUh?=
CCRF-CEM	NEfOZpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{f3OmlEPTB;MUGuOVk4KM7:TR?=	MmfyV2FPT0WU
SK-N-DZ	NIDH[nhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUm1Zm52UUN3ME2xNk4xPDN4IN88US=>	MV7TRW5ITVJ?
NCI-H720	NVPmbnRRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4HPT2lEPTB;MUKuNVcxPSEQvF2=	MV\TRW5ITVJ?
HCC1187	NGmy[5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4TXbWlEPTB;MUKuNlA1OSEQvF2=	Mm[2V2FPT0WU
IST-SL2	NVXkeoVHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NU\iTJdqUUN3ME2xNk41QDd{IN88US=>	NVzmboVQW0GQR1XS
KE-37	NHn4fYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1jqbGlEPTB;MUKuO\|k3PiEQvF2=	NU\ac4NGW0GQR1XS
HCC1599	M1XTeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnTZTWM2OD1zMj65NFY6KM7:TR?=	NIPSdZdUSU6JRWK=
A4-Fuk	NX30dmtmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVPJR\|UxRTF{Lkm1PFYh\|ryP	M1TTc3NCVkeHUh?=
NKM-1	M{XJemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGnWSJBKSzVyPUGzMlI6OjVizszN	NWjz[ZpIW0GQR1XS
BE-13	NVLwRWM1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV25NJE1UUN3ME2xN{44QTh7IN88US=>	NH3NTFdUSU6JRWK=
MV-4-11	MmPaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWLJR\|UxRTF2LkCzNlQh\|ryP	M4rORXNCVkeHUh?=
OPM-2	M3P3eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2DWb2lEPTB;MUSuOFA5PSEQvF2=	NF3pb2pUSU6JRWK=
KARPAS-422	MmDiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MknqTWM2OD1zND61NVI3KM7:TR?=	MnTjV2FPT0WU
RPMI-8226	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1zwbWlEPTB;MUSuPFkyPSEQvF2=	MoHmV2FPT0WU
KARPAS-45	MkXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkHiTWM2OD1zNT63O\|E3KM7:TR?=	M4\rZnNCVkeHUh?=
SK-PN-DW	NF\PRVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M32xeGlEPTB;MUWuPFY{OSEQvF2=	MojaV2FPT0WU
LC-2	NELxe2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml3NTWM2OD1zNj6xOVA3KM7:TR?=	Mmq1V2FPT0WU
NCI-H1648	NIXqd\|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnjRTWM2OD1zNj6yOVQh\|ryP	M2XERnNCVkeHUh?=
RL95-2	M4DuZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV7JR\|UxRTF4LkO5O\|gh\|ryP	M2Hhc3NCVkeHUh?=
KNS-42	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mom4TWM2OD1zNj63Nlc1KM7:TR?=	Mo\0V2FPT0WU
RPMI-6666	NU\lS4YxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV33OoF4UUN3ME2xOk46OjFzIN88US=>	NHPQXJBUSU6JRWK=
SIG-M5	Mm\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV;0epk6UUN3ME2xO{4yQTB\|IN88US=>	NGjPbnlUSU6JRWK=
VA-ES-BJ	MoS3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4DoZmlEPTB;MUeuO\|Q2OSEQvF2=	NFv2Tm5USU6JRWK=
MONO-MAC-6	M3\kXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWfaNpdHUUN3ME2xO{46OzF{IN88US=>	NUizVYk4W0GQR1XS
LAN-6	Mlq3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHexNpFKSzVyPUG4Mlc2PTdizszN	NInTU5NUSU6JRWK=
A388	M3Hhdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIDaR3dKSzVyPUG5MlMxPTlizszN	M{PyeXNCVkeHUh?=
SK-NEP-1	NUTyWVRVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NY\aeFBoUUN3ME2yNE4zOTN{IN88US=>	M17yVHNCVkeHUh?=
TE-10	MnvkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3HqNWlEPTB;MkCuOVIzOSEQvF2=	NWS5XnVtW0GQR1XS
HL-60	NInwUZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFvrRVBKSzVyPUKwMlkxQTlizszN	NWHlfGp1W0GQR1XS
MC116	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWjl[IxoUUN3ME2yNU44OjJzIN88US=>	Mmm1V2FPT0WU
SW962	NXvMbno4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2n5c2lEPTB;MkGuO\|kyPSEQvF2=	MmmwV2FPT0WU
NOMO-1	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWXJR\|UxRTJ{Lk[1OlQh\|ryP	MoXrV2FPT0WU
CTB-1	NG\abVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWrJR\|UxRTJ{Lki2O\|Eh\|ryP	MliwV2FPT0WU
MRK-nu-1	NWPrU3hzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXzJR\|UxRTJ{LkmwO\|Qh\|ryP	NEDBRYlUSU6JRWK=
GR-ST	NUTV[5pXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHvXfHhKSzVyPUKzMlc3KM7:TR?=	M1v3VnNCVkeHUh?=
HH	MofrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWCwco1VUUN3ME2yOE4xODNizszN	MYLTRW5ITVJ?
NCI-H1963	NYn1XmN1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3ztTWlEPTB;MkSuNFc5OiEQvF2=	MWHTRW5ITVJ?
QIMR-WIL	M4fZd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYLJR\|UxRTJ2Lki3O\|Ih\|ryP	MX7TRW5ITVJ?
CGTH-W-1	M1TLcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGjnVW9KSzVyPUK1MlA4OjNizszN	NXjtcG4yW0GQR1XS
LP-1	MoryS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFHWVodKSzVyPUK1MlY2PTFizszN	MWPTRW5ITVJ?
NCI-H748	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF62dmVKSzVyPUK2MlUyOzdizszN	MkfBV2FPT0WU
PF-382	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHu5RVZKSzVyPUK3MlIzOjNizszN	MlTZV2FPT0WU
ATN-1	NYrlSWM5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXzwRXVbUUN3ME2yO{4{PzN{IN88US=>	NXS4PJJJW0GQR1XS
L-540	NY\hfodLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYHJR\|UxRTJ5Lk[0OVkh\|ryP	MX\TRW5ITVJ?
LXF-289	NYiwe3VqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3G4N2lEPTB;MkeuO\|UyQSEQvF2=	NILMZpFUSU6JRWK=
LS-513	NHe4UYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV\JR\|UxRTJ6LkG4NFch\|ryP	MYnTRW5ITVJ?
NCI-H1581	M3PpNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnvrTWM2OD1\|MD6zPVc3KM7:TR?=	NYPNe2xbW0GQR1XS
ES6	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYjodZBlUUN3ME2zNE43QDl7IN88US=>	NVToTGloW0GQR1XS
SW982	NXrjPIZET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXzJR\|UxRTNyLki1OlYh\|ryP	MUTTRW5ITVJ?
DOHH-2	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWTJR\|UxRTNzLkW4PVMh\|ryP	MVrTRW5ITVJ?
DB	NXXPNJZUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnrOTWM2OD1\|Mz65OFMyKM7:TR?=	MYfTRW5ITVJ?
MPP-89	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIDWUZpKSzVyPUO0MlE4PTZizszN	MmnKV2FPT0WU
LB831-BLC	NEjoWohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkjKTWM2OD1\|ND61NVg1KM7:TR?=	MoS3V2FPT0WU
NB5	NH;zdndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIixcmtKSzVyPUO0Mlg2OzVizszN	NVXnXGZtW0GQR1XS
GB-1	NWrjeFFnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUfGUVBlUUN3ME2zOU4xPDZ7IN88US=>	M2XEPHNCVkeHUh?=
TE-15	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFzXdXVKSzVyPUO1MlIzOzhizszN	NFTtRotUSU6JRWK=
LC4-1	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX;SSYtnUUN3ME2zOU4{QDR5IN88US=>	NF7qOFBUSU6JRWK=
NCI-H747	NHTlPItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVvJR\|UxRTN4LkGzOlkh\|ryP	M3P0cXNCVkeHUh?=
NTERA-S-cl-D1	NX\Md2tRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkHqTWM2OD1\|OD63N\|Q4KM7:TR?=	NWXadGd3W0GQR1XS
SK-MM-2	NHP1NJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NE\SU\|hKSzVyPUSwMlEyPDZizszN	NUDucWk5W0GQR1XS
TGW	NULXSmFOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVLqTYdPUUN3ME20NU4xPTZ\|IN88US=>	NFHBUopUSU6JRWK=
ONS-76	NIPtXZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVfJR\|UxRTR{LkS4PFMh\|ryP	NVjLe\|VjW0GQR1XS
CPC-N	NH\pS3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYTQb4MyUUN3ME20Nk46QTdzIN88US=>	MnjpV2FPT0WU
ES4	NIDvWGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnXUTWM2OD12ND60NVU{KM7:TR?=	MoXvV2FPT0WU
Daudi	NGX3colIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{naS2lEPTB;NEWuNFgzPyEQvF2=	NH\rWppUSU6JRWK=
MOLT-4	NVrlNGRZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWLJR\|UxRTR3LkC4OVMh\|ryP	MYfTRW5ITVJ?
HT-144	NYPXd3NpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVPFdIhRUUN3ME20Ok44OjZizszN	MknXV2FPT0WU
SW872	M2jDemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NITObZlKSzVyPUS4MlE6OzNizszN	MV;TRW5ITVJ?
D-283MED	MlrwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoPGTWM2OD12OD6zOVQzKM7:TR?=	Ml;GV2FPT0WU
NCI-H2126	M{frPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIHmOJBKSzVyPUS4Mlg1PzZizszN	NHT1b5RUSU6JRWK=
NCI-SNU-16	M2j5fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWjnenBMUUN3ME20PU4zOTR\|IN88US=>	M1HOT3NCVkeHUh?=
CESS	NX6wRlBOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXHJR\|UxRTR7LkWwPFgh\|ryP	MYrTRW5ITVJ?
A101D	NXvmN2hYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUDJR\|UxRTR7Lkm3N\|Yh\|ryP	M1L2NnNCVkeHUh?=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	pALK / pAKT / pERK / pS6; PubMed: 24675041 Cancer Discov H3122 cells were treated with the indicated concentrations of crizotinib or ceritinib for 6 hours. Lysates were probed with antibodies directed against the specified proteins. pROS1 / ROS1; PubMed: 25351743 Clin Cancer Res Inhibition of phospho-ROS1 by various ALK inhibitors in Ba/F3 models. CD74-ROS1 expressing Ba/F3 cells were exposed to increasing concentrations of crizotinib, ceritinib, AP26113, or ASP3026 for 3 h. Cell lysates were immunoblotted to detect the indicated proteins. pSTAT3 / STAT3; PubMed: 25351743 Clin Cancer Res Inhibition of phospho-ROS1 by various ALK inhibitors in Ba/F3 models. CD74-ROS1 expressing Ba/F3 cells were exposed to increasing concentrations of crizotinib, ceritinib, AP26113, or ASP3026 for 3 h. Cell lysates were immunoblotted to detect the indicated proteins. PARP / cleaved caspase-3 / Bax / Bcl-2; PubMed: 25193856 Oncotarget The expression of PARP, cleaved caspase-3, Bax, and Bcl-2 were measured by western blotting after PANC-1 cells were treated with various concentrations of Crizotinib (0-10 μM) for 72 hr. p-c-Met / c-Met; PubMed: 25193856 Oncotarget Cancer cells with c-MET alterations were exposed to Crizotinib (10 μM) in the indicated times (SNU-5, MKN-45, and SNU-638: gastric cancer cells of c-MET amplification). p-mTOR; PubMed: 26384345 Oncotarget Immunoblotting for phospho- or total MET, STAT3, AKT, MTOR and ERK in SPC-A1 cells treated with crizotinib for 48 h.	24675041 25351743 25193856 26384345
Immunofluorescence	LC3 / lysosome; PubMed: 26384345 Oncotarget Cells were treated with DMSO or 4 μM crizotinib for 72 h before they were labeled with a fluorescent marker and imaged by fluorescence microscopy. Green: FITC-labeled LC3; Red: lyso-tracker-labeled lysosome; Blue: DAPI-labeled nucleus. SRC / Met; PubMed: 26517812 Oncotarget Cellular localization of SRC and Met following treatment for 48 h with dasatinib, crizotinib or combination in (A) LN-18 and (B) U373 cells. Scale bar denotes 10 μm. Nuclei were visualized by DAPI while SRC and Met were labeled with a fluorescein and Texas-red conjugated secondary antibodies, respectively. α-tubulin; PubMed: 26517812 Oncotarget LN-18 cells were treated with dasatinib 0.2 μM, crizotinib 4 μM or their combination for 48 h. Mitotic spindle were visualized using α-tubulin antibody conjugated to a fluorescein-labeled secondary antibody. Nuclei were stained by DAPI. The scale bar denotes 10 μm. cytochrome c; PubMed: 25193856 Oncotarget PANC-1 pancreatic cancer cells were treated with Crizotinib (1 and 10 μM) for 6 hr and stained with anti-cytochrome c antibody, Mitotracker and DAPI. The immunostained cells were analyzed under an Olympus confocal laser scanning microscope with 400x magnification. Cytochrome c (green), mitotracker: red p-ALK; PubMed: 25193856 Oncotarget PANC-1 cells were also treated with various concentrations (0-10 μM) of Crizotinib and stained with p-ALK antibody and DAPI. The immunostained cells were analyzed under an Olympus confocal laser scanning microscope with 400x magnification.	26384345 26517812 25193856

体内研究

PF-2341066每天按50 mg/kg和75 mg/kg剂量处理GTL-16 模型, 引起大肿瘤 (体积大于600 mm³) 明显衰退，且按43天处理日程处理后，平均肿瘤体积降低60%。在另一项研究中, PF-2341066处理3个月以上，完全抑制GTL-16肿瘤生长，PF-2341066每天按50 mg/kg剂量处理小鼠，3个月后，只有1/12小鼠的肿瘤生长得到提高。PF-2341066每天按50 mg/kg剂量处理NCI-H441 NSCLC 模型处理周期为38天，观察到平均肿瘤体积降低43%。PF-2341066 每天按50 mg/kg剂量作用于 Caki-1 RCC模型，处理周期为33天，观察到平均肿瘤体积降低53%，且每种肿瘤体积降低至少30%。PF-2341066每天按 50 mg/kg剂量作用于 U87MG 恶性胶质瘤或PC-3前列腺癌移植瘤模型,几乎完全抑制肿瘤生长，在实验最后一天，抑制分别达97% 或84%。相反, PF-2341066每天按50 mg/kg剂量口服给药处理 MDA-MB-231 乳腺癌模型,或 DLD-1 结肠癌模型，不会显著抑制肿瘤生长。PF-2341066每天按12.5 mg/kg, 25 mg/kg, 和50 mg/kg剂量作用于 GTL-16 肿瘤，观察到CD31阳性内皮细胞显著降低，这种作用存在剂量依赖性，说明 MVD 受抑制，且具有相关的抗癌高效性，这种作用也存在剂量依赖性。PF-2341066 作用于GTL-16 和 U87MG 模型，显著降低人VEGFA 和IL-8血浆水平，这种作用存在剂量依赖性。PF-2341066口服处理GTL-16 肿瘤，观察到磷酸化的c-Met, Akt, Erk, PLCλ1,和 STAT5水平显著受抑制。^[1]PF-2341066 每天按100 mg/kg剂量口服处理携带Karpas299 ALCL 移植瘤的SCID Beige 小鼠，具有抗癌高效性，这种作用存在剂量依赖性，处理15天，所有肿瘤完全衰退。此外, PF-2341066抑制关键NPM-ALK信号调节器, 包括磷脂酶C-γ, 信号转导器，及转录因子3, 细胞外信号调节激酶, 和Akt的激活剂，这些与 NPM-ALK 磷酸化和功能受抑制相关。^[2] PF-2341066 抑制骨肉瘤的一些活动行为，及其肿瘤生长(例如, 增殖和存活)和转移 (例如，入侵和形成克隆)。PF-2341066口服饲喂裸鼠，抑制生长和相关的骨肉瘤裸鼠移植瘤的骨基质的形成。^[3] PF-2341066 按50 mg/kg 剂量处理 c-MET-扩增的GTL-16移植瘤，引起肿瘤衰退，这与¹⁸F-FDG 摄取的缓慢降低相关，且降低葡糖糖转运蛋白 1, GLUT-1的表达。^[4]

激酶实验： ^[1]	- 合并生化激酶实验: 使用连续耦合的分光光度测定c-Met催化活性，通过分析NADH消耗率而测定c-Met诱导的ADP产量，这种作用具有时间依赖性。在 340 nm处使用分光光度法在指定时间点测定吸光值的降低而计算NADH的消耗量。为了测定K_i值, 在含实验试剂的实验孔中加入不同浓度PF-2341066，然后在37^oC下温育10分钟。加入c-Met酶开始进行实验反应。
细胞实验： ^[1]	- 合并 Cell lines: GTL-16胃癌细胞和T47D乳腺癌细胞 Concentrations: 0 nM-256 nM Incubation Time: 1小时 Method: GTL-16胃癌细胞和T47D乳腺癌细胞接种在96孔板上，孔中含培养基，培养基中含10% 胎牛血清(FBS)，然后转移到无血清培养基中[含0.04%牛血清蛋白(BSA)]，处理 24小时。在调查配体依赖的RTK 磷酸化实验中，加入相应的生长因子，处理20分钟。细胞和 PF-2341066和/或适当配体在指定时间温育1小时，然后使用含 1 mmol/L Na₃VO₄的HBSS冲洗细胞一次,然后从细胞中获得蛋白裂解物。随后,通过夹心酶联免疫吸附试验法使用特定的捕获抗体在96孔板上测定选定蛋白激酶的磷酸化，使用特点检测抗体测定磷酸化的酪氨酸残基。抗体包被的实验板(a) 在蛋白裂解物存在时，在4^oC下过夜;(b)在溶于PBS的1% Tween-20 中冲洗7次;(c)在辣根过氧化物酶标记的抗总磷酸（PY-20）抗体（1:500）中温育20分钟;(d) 再次冲洗7次;(e)在3,3^′,5,5^′-四甲基联苯胺过氧化物酶底物中温育，开始显示反应，加入0.09 N H₂SO₄终止反应; (f)在450 nm 处使用分光光度计测定吸光度。 (Only for Reference)
动物实验： ^[1]	- 合并 Animal Models: 携带NCI-H441,或DLD-1,或MDA-MB-231的雌性和雄性nu/nu小鼠 Dosages: 12.5 mg/kg/day, 25 mg/kg/day, 和50 mg/kg/day Administration: 口服处理 (Only for Reference)

参考文献

- 合并

溶解度 (25°C)

体外	DMSO	9 mg/mL (19.98 mM)
	Water	Insoluble
	Ethanol	Insoluble
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 5% DMSO+30% PEG 300+dd H2O	5mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download Crizotinib (PF-02341066) SDF

分子量	450.34
化学式	C₂₁H₂₂Cl₂FN₅O
CAS号	877399-52-5
储存条件	3年-20°C 粉状 2年-80°C 溶于溶剂
别名	N/A

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

每只动物给药体积

动物数量

只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO+ % + % Tween 80+ % ddH₂O

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

注意：1. 首先保证母液是澄清的；
2. 一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

临床试验信息 (data from https://clinicaltrials.gov, updated on 2020-05-15)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04148066	Recruiting	Diagnostic Test: ctDNA blood sample	Carcinoma Non-Small-Cell Lung	The Netherlands Cancer Institute\|Roche Pharma AG	July 17 2019	Phase 2
NCT03439215	Recruiting	Drug: Lorlatinib	Carcinoma Non-Small-Cell Lung	Fondazione Ricerca Traslazionale\|Clinical Research Technology S.r.l.	June 13 2017	Phase 2
NCT02946216	Unknown status	Genetic: ctDNA analysis	Non-small Cell Lung Cancer Stage III\|Non-Small-Cell Lung Cancer Metastatic\|Adenocarcinoma of Lung\|EGFR Wildtype	First People''s Hospital of Hangzhou	November 2016	--
NCT02511184	Terminated	Drug: Crizotinib\|Drug: Pembrolizumab	ALK-positive Advanced NSCLC	Pfizer\|Merck Sharp & Dohme Corp.	October 2015	Phase 1
NCT02419287	Unknown status	Drug: crizotinib	Anaplastic Large Cell Lymphoma ALK-Positive	University of Milano Bicocca	April 2015	Phase 2
NCT02499614	Unknown status	Drug: Crizotinib	Carcinoma Non-Small-Cell Lung	Fondazione Ricerca Traslazionale	December 2014	Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

常见问题及建议解决方法

问题 1：
Could you tell me whether this product represents the pure R-form of crizotinib, or is the the racemic Crizotinib, so a mixture of the S- and the R-form?
回答：
Our S1068 Crizotinib is R enantiomer(except batch 05 and 06, they are racemate), and S7505 is S enantiomer.

c-Met Signaling Pathway Map

c-Met Inhibitors with Unique Features

选择性强的c-Met抑制剂

PF-04217903 : C-Met-selective, IC50=4.8 nM.
活性最高的c-Met抑制剂

INCB28060 : C-Met, IC50=0.13 nM.
用于临床的c-Met抑制剂

Tivantinib (ARQ 197) : Phase III for Hepatocellular Carcinoma.
最新的c-Met抑制剂

EMD 1214063 ^New : Potent and selective c-Met inhibitor with IC50 of 4 nM, >200-fold selective for c-Met than IRAK4, TrkA, Axl, IRAK1, and Mer.

研究领域

产品类型

Crizotinib (PF-02341066)

客户使用Selleck生产的Crizotinib (PF-02341066)发表文献255篇：

产品安全说明书

c-Met抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download Crizotinib (PF-02341066) SDF

动物体内配方计算器 (澄清溶液)

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

临床试验信息 (data from https://clinicaltrials.gov, updated on 2020-05-15)

技术支持

常见问题及建议解决方法

c-Met Signaling Pathway Map

c-Met Inhibitors with Unique Features

相关c-Met产品